Cartesian Therapeutics (RNAC) Operating Expenses (2016 - 2025)
Historic Operating Expenses for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $21.5 million.
- Cartesian Therapeutics' Operating Expenses rose 1979.73% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.6 million, marking a year-over-year decrease of 872.27%. This contributed to the annual value of $82.8 million for FY2024, which is 2633.87% down from last year.
- According to the latest figures from Q3 2025, Cartesian Therapeutics' Operating Expenses is $21.5 million, which was up 1979.73% from $22.1 million recorded in Q2 2025.
- Over the past 5 years, Cartesian Therapeutics' Operating Expenses peaked at $44.6 million during Q4 2023, and registered a low of $18.0 million during Q3 2024.
- In the last 5 years, Cartesian Therapeutics' Operating Expenses had a median value of $23.0 million in 2025 and averaged $23.6 million.
- Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 7633.94% in 2023, then tumbled by 4176.42% in 2024.
- Quarter analysis of 5 years shows Cartesian Therapeutics' Operating Expenses stood at $25.9 million in 2021, then fell by 2.2% to $25.3 million in 2022, then soared by 76.34% to $44.6 million in 2023, then plummeted by 41.76% to $26.0 million in 2024, then fell by 17.15% to $21.5 million in 2025.
- Its Operating Expenses was $21.5 million in Q3 2025, compared to $22.1 million in Q2 2025 and $23.0 million in Q1 2025.